GLP-1, GIP, and Glucagon Triple Agonists for Neurodegeneration <table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Triple Incretin Agonists (GLP-1/GIP/Glucagon) for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BI-456906</td>
<td>Boehringer</td>
</tr>
</table>
Introduction Triple Incretin Agonists (Glp 1 Gip Glucagon) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
flowchart TD
Triple_Incretin_Agonists__GLP_["Triple Incretin Agonists GLP-1/GIP/Glucagon for "]
Triple_Incretin_Agonists__GLP_["GLP-1"]
Triple_Incretin_Agonists__GLP_ -->|"related to"| Triple_Incretin_Agonists__GLP_
style Triple_Incretin_Agonists__GLP_ fill:#81c784,stroke:#333,color:#000
Triple_Incretin_Agonists__GLP_["Glucagon"]
Triple_Incretin_Agonists__GLP_ -->|"related to"| Triple_Incretin_Agonists__GLP_
style Triple_Incretin_Agonists__GLP_ fill:#81c784,stroke:#333,color:#000
Triple_Incretin_Agonists__GLP_["table"]
Triple_Incretin_Agonists__GLP_ -->|"related to"| Triple_Incretin_Agonists__GLP_
style Triple_Incretin_Agonists__GLP_ fill:#81c784,stroke:#333,color:#000
style Triple_Incretin_Agonists__GLP_ fill:#4fc3f7,stroke:#333,color:#000
...
GLP-1, GIP, and Glucagon Triple Agonists for Neurodegeneration <table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Triple Incretin Agonists (GLP-1/GIP/Glucagon) for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BI-456906</td>
<td>Boehringer</td>
</tr>
</table>
Introduction Triple Incretin Agonists (Glp 1 Gip Glucagon) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Combination agonists targeting multiple incretin receptors (GLP-1, GIP, and glucagon) represent a novel approach to treating neurodegenerative diseases. These multi-receptor agonists leverage synergistic effects on glucose metabolism, neuroprotection, and neuroinflammation. [@athauda2018]
Molecular Mechanism
Receptor Targets
[GLP-1 Receptor](/entities/glp1-receptor) (GLP-1R) : Glucose-dependent insulin secretion, satiety, neuroprotectionGIP Receptor (GIP-R) : Incretin effect, potential cognitive benefitsGlucagon Receptor (GCGR) : Energy expenditure, lipolysis, hepatic effects
Signaling Pathways
cAMP/PKA : Modulates neuronal survival and synaptic plasticityPI3K/Akt : Promotes neuroprotection and mitochondrial functionAMPK : Energy homeostasis, [autophagy](/entities/autophagy) inductionERK/MAPK : Synaptic plasticity and memory formationNeuroprotective Mechanisms
Reduced neuroinflammation : Decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)Enhanced autophagy : Improved clearance of misfolded proteinsMitochondrial protection : Reduced oxidative stress, improved ATP productionSynaptic preservation : Protection against excitotoxicity[Amyloid-beta](/proteins/amyloid-beta) clearance : Enhanced [Aβ](/proteins/amyloid-beta) degradation[Tau](/proteins/tau) phosphorylation regulation : Modulation of kinase/phosphatase balanceTriple Agonists in Development
Tirzepatide (Mounjaro)
Targets : GIP/GLP-1 dual agonist (approved for diabetes)Neurodegeneration potential : Being investigated for AD and PDClinical trials : Phase 2 trials in MCI and early ADRetatrutide (LY343)
Targets : GIP/GLP-1/glucagon triple agonistStage : Phase 2 for obesity/diabetes, exploring neurodegenerative applicationsAdvantages : Most potent incretin-based therapyNovel Triple Agonists
Disease-Specific Applications
Alzheimer's Disease Triple agonists may provide: [@finan2025]
Improved cerebral glucose metabolism
Reduced amyloid plaque burden
[Tau](/proteins/tau) pathology modification
Cognitive function preservation
Reduced neuroinflammation
Parkinson's Disease Potential benefits:
Neuroprotection of dopaminergic [neurons](/entities/neurons)
Improved motor function
Reduced [α-synuclein](/proteins/alpha-synuclein) aggregation
Enhanced mitochondrial function
ALS Emerging evidence suggests:
Motor neuron protection
Reduced inflammation
Improved energy metabolism
Huntington's Disease
Potential cognitive and motor benefits
Metabolic improvements
Neuroprotective effects
Clinical Considerations
Advantages Over Single Agonists
Enhanced efficacy : Synergistic receptor activationDose optimization : Lower doses may achieve greater effectsBroader therapeutic window : Balanced receptor activationMetabolic benefits : Weight loss, improved glycemic control
Safety Profile
Common adverse events : Nausea, vomiting, diarrhea (dose-dependent)Pancreatitis risk : Monitor in patients with historyThyroid C-cell tumors : Contraindicated in MEN2 historyInjection site reactions : Generally mildBiomarkers for Response
CSF [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL)
Amyloid/tau biomarkers in CSF and plasma
Metabolic markers (HbA1c, weight)
Cognitive assessment scales
Research Directions
[Blood-brain barrier](/entities/blood-brain-barrier) penetration : Optimizing CNS deliveryOral formulations : Improving bioavailabilityCombination approaches : With other disease-modifying therapiesBiomarker development : Patient stratificationPreventive use : Targeting at-risk populationsSee Also
[GLP-1 Receptor Agonists for Neurodegeneration](/therapeutics/glp-1-receptor-agonists-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Metabolic Dysfunction Pathway](/mechanisms/metabolic-dysfunction-pathway)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
[Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
[Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
Background The study of Triple Incretin Agonists (Glp 1 Gip Glucagon) For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[GIP Receptor - UniProt](https://www.uniprot.org/uniprotkb/P09681)
[GLP-1 Receptor - UniProt](https://www.uniprot.org/uniprotkb/P43220)
[ClinicalTrials.gov - Incretin and Neurodegeneration](https://clinicaltrials.gov/search?cond=Alzheimer&intr=GLP-1)
References
Unknown, Hölscher C. Novel dual GLP-1/GIP receptor agonists are neuroprotective in animal models of Alzheimer's disease. Neurobiol Aging. 2014;35(9):1977-1985 (2014)
Athauda D, Foltynie T, The glucagon-like peptide 1 analogue exenatide in Parkinson's disease: a randomised controlled study (2018)
Yildirim Dow E, et al, The role of GIP in the brain (2020)
Yang L, et al, Tirzepatide: a novel dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity (2022)
Salameh TS, et al, GLP-1 receptor agonists and neurodegenerative disease: new perspectives on molecular mechanisms (2023)
Mulvihill EE, GIP receptor biology and therapeutic potential (2024)
Belsi E, et al, Triple GLP-1/GIP/Glucagon agonists: a new frontier in metabolic disease treatment (2024)
Finan B, et al, Chemical hybridization of glucagon and GLP-1 results in therapeutic agents for metabolic disease (2025)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Show full description